- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Alamar Biosciences, Inc.: Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team | 114 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR) a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced... ► Artikel lesen | |
| 25.09. | Alamar Biosciences, Inc.: Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment | 1 | GlobeNewswire (USA) | ||
| 24.09. | Alamar Biosciences stock rating reiterated at Buy by TD Cowen | 1 | Investing.com | ||
| 21.09. | Alamar Biosciences: Starke Quartalszahlen und erhöhte Prognose beflügeln die Aktie | 3 | Investing.com Deutsch | ||
| 12.08. | Biotech Stocks At 52-Week Highs - Alamar Biosciences +30% on Q2 Reports, Dyne Therapeutics, Cullinan Therapeutics, DexCom, Cardinal Health | 2.684 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc.... ► Artikel lesen | |
| 11.08. | Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum | 2 | Benzinga.com | ||
| 11.08. | Stifel raises Alamar Biosciences stock price target on earnings beat | 1 | Investing.com | ||
| ALAMAR BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 11.08. | Alamar outlines $116M-$120M 2026 revenue outlook while targeting 100+ instruments and $400,000+ pull-through | 1 | Seeking Alpha | ||
| 10.08. | Alamar Q2 2026 slides: consumables surge 147%, margin hits 60% | 1 | Investing.com | ||
| 10.08. | Alamar Biosciences: Starkes Umsatzwachstum und Rekordmarge bei anhaltenden Verlusten | 4 | Investing.com Deutsch | ||
| 10.08. | Alamar Biosciences expands proteomics partnership by 86,000 samples | 3 | Investing.com | ||
| 10.08. | Alamar Biosciences erweitert Proteomik-Partnerschaft um 86.000 Proben | - | Investing.com Deutsch | ||
| 10.08. | Alamar Biosciences, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 10.08. | Alamar Biosciences, Inc.: Alamar Biosciences Expands Global Partnership with Alzheimer's Disease Data Initiative and Gates Ventures | 3 | GlobeNewswire (USA) | ||
| 28.07. | Alamar Biosciences launches immune profiling panel for research | 1 | Investing.com | ||
| 28.07. | Alamar Biosciences stellt neues Panel zur Immunprofilierung für die Forschung vor | 2 | Investing.com Deutsch | ||
| 28.07. | Alamar Biosciences, Inc.: Alamar Biosciences Launches NULISAseq Immune 340 Panel for Comprehensive Profiling of the Immune Proteome | 490 | GlobeNewswire (Europe) | Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging
Highly sensitive... ► Artikel lesen | |
| 27.07. | Cathie Woods Biotech-Offensive lenkt den Blick auf datengetriebene Healthcare-Unternehmen - Emyria baut klinische Präsenz aus | Small- & Micro Cap Investment | |||
| 15.07. | Alamar Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | Health Wave Partners Acquires Alamar Senior Living | 1 | pulse2.com |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS | 27,430 | 0,00 % | Amylyx Pharma Q2 2026 Earnings Call Transcript | ||
| TANGO THERAPEUTICS | 21,830 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| QIAGEN | 40,800 | +0,64 % | AKTIEN IM FOKUS: Aktien aus Diagnostik- und Laborbranche gesucht | FRANKFURT (dpa-AFX) - Aktien aus dem Segment Wirkstoffforschung, Diagnostik und Laborausrüstung haben am Dienstag auf den Kauflisten von Anlegern gestanden. Den Dax führten die Papiere von Qiagen und... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,960 | +0,06 % | Novo Nordisk zahlt bis zu 2,6 Milliarden Dollar für Biotech - warum Eli Lilly, GSK und AstraZeneca ebenfalls Milliarden auf neue Technologien setzen | ||
| CG ONCOLOGY | 62,38 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,140 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,265 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| NURIX THERAPEUTICS | 22,730 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 278,18 | +0,06 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| VERA THERAPEUTICS | 30,260 | +0,03 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,140 | 0,00 % | BMO reiterates Trevi Therapeutics stock rating after rival study fails | ||
| ARRIVENT BIOPHARMA | 16,890 | 0,00 % | BTIG cuts ArriVent BioPharma stock price target on trial results | ||
| DYNE THERAPEUTICS | 15,975 | +0,03 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 26,680 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 108,36 | +0,01 % | Citi raises Kymera Therapeutics stock price target on drug potential |
ALAMAR BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 27,770 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALAMAR BIOSCIENCES INC finden Sie auf Wallstreet Online.